Rhenman & Partners Asset Management AB - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 159 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.

Quarter-by-quarter ownership
Rhenman & Partners Asset Management AB ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2020$2,518,000
-49.2%
40,0000.0%0.35%
-35.0%
Q4 2019$4,957,000
+56.9%
40,000
-16.0%
0.54%
+37.1%
Q3 2019$3,159,000
+5.6%
47,600
+26.6%
0.40%
+20.0%
Q2 2019$2,992,000
+33.0%
37,600
-2.3%
0.33%
+8.6%
Q4 2017$2,249,000
-3.1%
38,500
-3.8%
0.30%
+2.7%
Q3 2017$2,322,000
+537.9%
40,000
+1229.8%
0.30%
+469.2%
Q2 2017$364,000
-89.3%
3,008
-90.0%
0.05%
-90.3%
Q1 2017$3,393,000
+56.1%
30,000
+50.0%
0.54%
+28.8%
Q4 2016$2,173,000
-99.9%
20,000
+100.0%
0.42%
+59.8%
Q3 2016$1,645,900,000
+42287.3%
10,000
-61.5%
0.26%
-55.5%
Q4 2015$3,883,000
-26.8%
26,000
-18.8%
0.59%
-30.6%
Q3 2015$5,308,000
-8.4%
32,000
+33.3%
0.85%
+21.6%
Q2 2015$5,793,000
-10.7%
24,000
+4.3%
0.70%
-36.4%
Q1 2015$6,486,000
+89.0%
23,000
+4.5%
1.09%
+9.9%
Q4 2014$3,432,000
-22.0%
22,000
+18.3%
1.00%
-22.8%
Q3 2014$4,402,00018,6001.29%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2017
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$53,308,00010.69%
Senvest Management, LLC 976,127$81,907,0005.65%
Melqart Asset Management (UK) Ltd 390,600$32,775,0002.80%
Asymmetry Capital Management, L.P. 25,918$2,175,0002.14%
Elk Creek Partners, LLC 386,397$32,423,0001.78%
BB BIOTECH AG 545,719$45,791,0001.32%
ALTRINSIC GLOBAL ADVISORS LLC 383,166$32,151,0001.27%
DLD Asset Management, LP 129,000$10,824,0000.82%
Opus Point Partners Management, LLC 3,998$335,0000.73%
Virtus ETF Advisers LLC 8,970$753,0000.67%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders